LYON, France--(BUSINESS WIRE)--Flamel Technologies (Nasdaq:FLML) is pleased that the U.S. FDA has approved GlaxoSmithKline’s (NYSE:GSK) new drug application of COREG CR (carvedilol phosphate extended release capsules) for use in treating three key conditions:
